相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction
Chao Yang et al.
SCIENTIFIC REPORTS (2017)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
Inhibition of TLR1/2 dimerization by enantiomers of metal complexes
Li-Juan Liu et al.
CHEMICAL COMMUNICATIONS (2016)
Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) N-Heterocyclic Carbene Complexes
Yvonne Gothe et al.
CHEMISTRY-A EUROPEAN JOURNAL (2016)
Themed Issue on Metallodrugs: Activation, Targeting, and Delivery
Nils Metzler-Nolte et al.
DALTON TRANSACTIONS (2016)
Biscylometalated iridium(III) complexes target mitochondria or lysosomes by regulating the lipophilicity of the main ligands
Kangqiang Qiu et al.
DALTON TRANSACTIONS (2016)
Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α
Tian-Shu Kang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge
Duncan E. Scott et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Systematic Targeting of Protein-Protein Interactions
Ashley E. Modell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds
Li-Juan Liu et al.
ONCOTARGET (2016)
Antagonizing STAT5B dimerization with an osmium complex
Li-Juan Liu et al.
SCIENTIFIC REPORTS (2016)
BSA as additive: A simple strategy for practical applications of PNA in bioanalysis
Jieon Lee et al.
BIOSENSORS & BIOELECTRONICS (2015)
Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(i)–NHC complex
Y. Gothe et al.
CHEMICAL COMMUNICATIONS (2015)
Protein-protein interactions as drug targets
Malgorzata Skwarczynska et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Toward organometallic antischistosomal drug candidates
Jeannine Hess et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Correlation between the Stereochemistry and Bioactivity in Octahedral Rhodium Prolinato Complexes
Rajathees Rajaratnam et al.
INORGANIC CHEMISTRY (2015)
Sorafenib for patients with differentiated thyroid cancer
Pascaline Boudou-Rouquette et al.
LANCET (2015)
An iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent
Hai-Jing Zhong et al.
CHEMICAL SCIENCE (2015)
Group 9 Organometallic Compounds for Therapeutic and Bioanalytical Applications
Dik-Lung Ma et al.
ACCOUNTS OF CHEMICAL RESEARCH (2014)
Antagonizing STAT3 Dimerization with a Rhodium(III) Complex
Dik-Lung Ma et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Targeting Protein-Protein Interaction by Small Molecules
Lingyan Jin et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
RAF neighborhood: Protein-protein interaction in the Raf/Mek/Erk pathway
Botond Cseh et al.
FEBS LETTERS (2014)
Antagonism of mTOR Activity by a Kinetically Inert Rhodium(III) Complex
Hai-Jing Zhong et al.
CHEMPLUSCHEM (2014)
Determining target engagement in living systems
Gabriel M. Simon et al.
NATURE CHEMICAL BIOLOGY (2013)
Targeting protein-protein interactions as an anticancer strategy
Andrei A. Ivanov et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
RAS/RAF/MEK Inhibitors in Oncology
M. Broggini
CURRENT MEDICINAL CHEMISTRY (2012)
New half sandwich Ru(II) coordination compounds for anticancer activity
Ioannis Bratsos et al.
DALTON TRANSACTIONS (2012)
Structure-based prediction of protein-protein interactions on a genome-wide scale
Qiangfeng Cliff Zhang et al.
NATURE (2012)
Crystal structure of Δ-[Ru(bpy)2dppz]2+ bound to mismatched DNA reveals side-by-side metalloinsertion and intercalation
Hang Song et al.
NATURE CHEMISTRY (2012)
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Michael Frezza et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Interactome under construction
Laura Bonetta
NATURE (2010)
A Ruthenium-Containing Organometallic Compound Reduces Tumor Growth through Induction of the Endoplasmic Reticulum Stress Gene CHOP
Xiangjun Meng et al.
CANCER RESEARCH (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raf kinases: Function, regulation and role in human cancer
Deborah T. Leicht et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway
H Waldmann et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang et al.
LEUKEMIA (2003)
Design of inhibitors of Ras-Raf interaction using a computational combinatorial algorithm
J Zeng et al.
PROTEIN ENGINEERING (2001)
分享论文
